1. Home
  2. Live Updates
  3. Jorge nieva

Live Breaking News & Updates on Jorge nieva

Stay informed with the latest breaking news from Jorge nieva on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Jorge nieva and stay connected to the pulse of your community

Study explores the future of at-home cancer treatment

A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.

United-states , Sandy-tran , Jorge-nieva , Drug-administration , Norris-comprehensive-cancer-center , National-cancer-institute , Genentech-inc , Keck-medicine , Comprehensive-cancer-center , Newswise , Lincal-trial-immunotherapy-clinical-trials-cancer , Cancer

Study explores the future of at-home cancer treatment

A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.

United-states , Jorge-nieva , Sandy-tran , Genentech-inc , National-cancer-institute , Norris-comprehensive-cancer-center , Drug-administration , Keck-medicine , Comprehensive-cancer-center ,

Dr Nieva on the Rationale for Investigating At-Home Atezolizumab Administration in NSCLC

Jorge Nieva, MD, discusses the rationale and design of an ongoing phase 2 trial investigating a telemedicine approach to delivering subcutaneous atezolizumab for patients with non–small cell lung cancer.

Jorge-nieva , Keck-school-of-medicine , University-of-southern-california , Keck-school , Southern-california , D , Nct05340309 , Subcutaneous-atezolizumab , Patients-with-non-small-cell-lung-cancer- ,

FDA Panel Votes That Phase 3 PFS Data for Sotorasib in KRAS G12C+ Advanced NSCLC Cannot Be Reliably Interpreted

In a 10-to-2 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the data for progression-free survival per blinded independent central review from the phase 3 CodeBreaK 200 trial evaluating sotorasib vs docetaxel for the treatment of patients with pretreated, locally advanced or metastatic KRAS G12C–mutated non–small cell lung cancer cannot be reliably interpreted.

Markr-conaway , Jorge-nieva , Ravia-madan , Jeevan-puthiamadathil , Division-of-translational-research , University-of-virginia-school-medicine , National-cancer-institute , Keck-school-of-medicine , Statistics-department-of-public-health-sciences , University-of-southern-california , Oncologic-drugs-advisory-committee , Drugs-advisory-committee

Immunotherapy in Lung Cancer: Current Landscape and Future Directions

'There's going to be more immunotherapy trials coming,' says Jorge Nieva, MD

United-states , American , Greg-laub , Los-angeles , Jorge-nieva , Keck-school-of-medicine , American-society-of-clinical-oncology , University-of-southern-california , American-society , Clinical-oncology , Medpage-today , Keck-school

FDA Panel Rejects Broad Olaparib Indication in Metastatic CRPC

ODAC votes that olaparib-abiraterone combination should be restricted to <em>BRCA</em>-positive subset

California , United-states , North-carolina , Columbia-university , New-york , Colorado , Massachusetts , Mike-bassett , Chana-weinstock , Daniel-george , Los-angeles , Richard-pazdur

KaliVir Immunotherapeutics Establishes Clinical and Scientific Advisory Boards

KaliVir Immunotherapeutics Establishes Clinical and Scientific Advisory Boards - read this article along with other careers information, tips and advice on BioSpace

University-of-san-francisco , California , United-states , University-of-california-san-francisco , Lisa-butterfield , Kalivir-immunotherapeutics , Dmitriy-zamarin , Jonathan-rosenberg , Jorge-nieva , Astellas-pharma , Greg-delgoffe , Helena-chaye

KaliVir Immunotherapeutics Establishes Clinical and Scientific Advisory Boards

/PRNewswire/ -- KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today...

University-of-san-francisco , California , United-states , University-of-california-san-francisco , Lisa-butterfield , Kalivir-immunotherapeutics , Dmitriy-zamarin , Jonathan-rosenberg , Jorge-nieva , Astellas-pharma , Greg-delgoffe , Helena-chaye

FDA Panel Votes Against Omburtamab for Rare Pediatric Cancer

The FDA's ODAC voted unanimously that there was a lack of evidence to support approval of l-omburtamab for a rare pediatric cancer. The FDA has a November 30 deadline to decide if it will approve the drug.

Germany , United-states , German , Jorge-nieva , Diana-zuckerman , National-center , Oncologic-drugs-advisory-committee , Drug-administration , University-of-southern-california , Health-research , Memorial-sloan-kettering-cancer-center , Y-mabs-therapeutics

FDA Panel: All Thumbs Down for Antibody to Treat Metastatic Neuroblastoma

Questions about selection bias, control group, response data prompt 16-0 vote against omburtamab

Germany , Colorado , United-states , Delaware , German , Jorge-nieva , Los-angeles , E-anders-kolb , Charles-bankhead , Nemours-children-health-in-wilmington , Oncologic-drugs-advisory-committee , Norris-comprehensive-cancer-center